Table 2.
Baseline characteristics of newly diagnosed PCM patients based on expression of CD117 and CD81
| Parameter | CD117 expression | P value | CD81 expression | P value | ||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | |||
| n = 47 | n = 84 | n = 53 | n = 78 | |||
| Age ≥60 | 27 | 44 | 0.577 | 29 | 42 | 0.532 |
| Gender, male | 32 | 47 | 0.173 | 33 | 46 | 0.706 |
| ISS stage III | 11 | 39 | 0.009* | 27 | 23 | 0.013* |
| Monoclonal heavy chain | ||||||
| IgG | 27 | 35 | 0.599 | 26 | 36 | 0.369 |
| IgA | 7 | 17 | 10 | 14 | ||
| IgM | 0 | 1 | 0 | 1 | ||
| IgD | 2 | 7 | 6 | 3 | ||
| Light chain only | 10 | 20 | 8 | 22 | ||
| BM plasma cell ≥5% | 33 | 62 | 0.658 | 41 | 54 | 0.306 |
| Median beta‐2‐microglobulin, mg/L (range) | 4.91 (1.2‐25.9) | 5.48 (1.9‐76.2) | 0.000* | 5.47 (1.2‐76.2) | 5.22 (1.9‐38.1) | 0.000* |
| Median lactate dehydrogenase U/L (range) | 154 (85‐913) | 161 (53‐737) | 0.266 | 189 (60‐737) | 159 (53‐913) | 0.199 |
| Median albumin, g/dL (range) | 3.15 (1.3‐4.78) | 3.35 (1.64‐4.94) | 0.755 | 3.34 (1.3‐4.87) | 3.27 (1.35‐4.94) | 0.306 |
| Median calcium, mmol/L (range) | 2.06 (1.67‐4.02) | 2.22 (1.75‐4.04) | 0.593 | 2.31 (1.67‐4.04) | 2.16 (1.71‐3.1) | 0.001* |
| Median creatinine, µmol/L (range) | 88.2 (35.0‐1580.6) | 110.2 (38.3‐1692.9) | 0.268 | 102.7 (35.0‐1692.9) | 101.7 (45.2‐1156.6) | 0.001* |
| Median hemoglobin, g/dL (range) | 7.9 (3.0‐15.2) | 7.9 (4.0‐15.0) | 0.819 | 7.8 (4.0‐15.2) | 8.1 (3.0‐13.2) | 0.515 |
| Therapeutic protocol | ||||||
| Bortezomib‐based protocol | 17 | 30 | 0.958 | 16 | 31 | 0.263 |
| Thalidomide‐based protocol | 30 | 54 | 37 | 47 | ||
a
P < 0.05.